Abivax pares gain after denying AstraZeneca speculation
Source: SeekingAlpha
2026-03-12 10:41:35 ET
More on Abivax
- Abivax: Don't Just Buy The Rumor, Buy The Fundamentals
- Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
- Abivax CEO responds to Lilly acquisition rumors
- Key deals this week: Micron Technology, Worthington Steel, Boston Scientific, CrowdStrike and more
- Seeking Alpha’s Quant Rating on Abivax
Read the full article on Seeking Alpha
For further details see:
Abivax pares gain after denying AstraZeneca speculation
Abivax SA
NASDAQ: ABVX
ABVX Trading
-3.23% G/L:
$114.445 Last:
166,753 Volume:
$116.16 Open:
ABVX Latest News
March 23, 2026 04:05:00 pm
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
ABVX Stock Data
$9,359,969,582
53,161,297
N/A
64
N/A
Biotechnology & Life Sciences
Healthcare
FR
Paris
